The present invention discloses a Plectin-1 receptor targeting novel cationic KTLLPTPK-lipopeptide. The present invention further discloses a liposomal formulation comprising the cationic KTLLPTPK-lipopeptide, at least two co-lipids, therapeutic agents and a pharmaceutically acceptable carrier. The present invention also provides a method for regressing established pancreatic tumors comprising administering therapeutically effective amount of the liposomal formulation with the therapeutic agents in combination with targeted genetic immunization (DNA vaccination) i.e. by immunizing mice with electrostatic complexes (direct in-vivo DC-targeting cationic liposomes) of DNA vaccines encoding mesothelin (p-CMV-MSLN).
本发明公开了一种靶向Plectin-1受体的新型阳离子KTLL
PTPK-脂肽。本发明还公开了一种包含阳离子KTLL
PTPK-脂肽、至少两种共脂质、治疗剂和药用载体的脂质体制剂。本发明还提供了一种治疗已建立的胰腺肿瘤的方法,包括通过将含有治疗剂的脂质体制剂与靶向
基因免疫(DNA疫苗接种)结合的方式进行。即通过使用编码间皮细胞素(p-CMV-MSLN)的DNA疫苗的静电复合物(直接体内DC靶向阳离子脂质体)来免疫小鼠。